公司资料
BCR 股价、新闻与催化剂
- 股票代码:
- BCR
- 交易所:
- NYSE
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
Current closing-price context is not available for BCR.
公司概览
业务概览
C. R. Bard was a medical technology company with broad exposure to vascular, urology, and surgical products before being acquired by Becton Dickinson. It represented a durable device and procedure-driven healthcare franchise.
所在地与行业分类
Bard was headquartered in the United States and traded on NYSE before the acquisition. Its business was rooted in medical devices rather than biotech or pharma.
商业模式特征
The company generated revenue through procedure-linked products, hospital adoption, and recurring device demand. Investors historically watched product cycles, hospital purchasing, and the stability of its surgical and vascular franchise.
生物医药行业定位
Bard was outside biotech and closer to the medtech infrastructure layer. Since it was acquired, it is best treated as a historical healthcare infrastructure name.
未来催化剂
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。